Arrowhead presents new Phase 2 Data of plozasiran in hyperlipidemia

Arrowhead Pharmaceuticals announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran – formerly ARO-APOC3 – in patients with mixed hyperlipidemia. Treatment with plozasiran in the MUIR study achieved reductions in triglyceride rich lipoproteins, a genetically validated target associated with increased risk of atherosclerotic cardiovascular disease – ASCVD -. These data were presented at the European Atherosclerosis Society Congress and simultaneously published in the New England Journal of Medicine. The results from treatment with plozasiran in the MUIR study help to lay the groundwork for a more extensive study to potentially test whether plozasiran reduces ASCVD risk. By silencing Apolipoprotein C-III, plozasiran significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins and increased HDL, across all dose levels at Week 24 in patients with mixed dyslipidemia. Plozasiran treatment was associated with placebo adjusted reductions in triglycerides of -50%, -56%, and -62% at the 10, 25, and 50 mg doses, respectively. Fasting triglyceride levels were normalized in most patients – 79-92% – randomized to a treatment arm. Plozasiran demonstrated a favorable safety profile in the MUIR study.